论文部分内容阅读
目的:探讨吡格列酮(PGZ)对肥胖2型糖尿病(T2DM)患者炎症因子C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及单核细胞趋化蛋白-1(MCP-1)的影响。方法:将69例肥胖T2DM患者用随机双盲法分为PGZ组和常规组,另选取50例健康人作为正常对照,治疗前后分别用ELISA法检测患者血清CRP、TNF-α、IL-6和MCP-1水平。结果:与正常对照组比较,肥胖T2DM组血清CRP、TNF-α、IL-6和MCP-1水平显著升高(P<0.05);应用PGZ治疗后,患者血清上述炎症因子水平显著降低(P<0.05),而常规组治疗前后差异无统计学意义(P>0.05)。结论:PGZ能降低肥胖T2DM患者血清炎症因子水平,具有抗炎作用。
Objective: To investigate the effects of pioglitazone (PGZ) on the expression of inflammatory cytokines C reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and monocytes in patients with type 2 diabetes mellitus (T2DM) Effect of chemotactic protein-1 (MCP-1). Methods: Sixty-nine patients with obese T2DM were randomly divided into two groups: the PGZ group and the conventional group, and the other 50 healthy individuals were selected as the normal control. Serum levels of CRP, TNF-α, IL-6 and MCP-1 level. Results: Serum levels of CRP, TNF-α, IL-6 and MCP-1 in obese T2DM patients were significantly higher than those in normal controls (P <0.05). After treatment with PGZ, the levels of serum inflammatory cytokines <0.05), while there was no significant difference in the conventional group before and after treatment (P> 0.05). Conclusion: PGZ can reduce serum levels of inflammatory cytokines in obese T2DM patients and has anti-inflammatory effects.